Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 161, Issue 11, Pages 2115-2117Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.161.11.2115
Keywords
-
Categories
Funding
- NCRR NIH HHS [M01 RR-00750] Funding Source: Medline
- NIMH NIH HHS [K23 MH-068627] Funding Source: Medline
Ask authors/readers for more resources
Objective: The authors assessed the effects Of D-cycloserine on the core symptom of social impairment in subjects with autism. Method: Following a 2-week, single-blind placebo lead-in phase, drug-free subjects with autistic disorder were administered three different doses Of D-cycloserine during each of three 2-week periods. Measures used for subject ratings included the Clinical Global Impression (CGI) scale and Aberrant Behavior Checklist. Results: Significant improvement was found on the CGI and social withdrawal subscale of the Aberrant Behavior Checklist. D-Cycloserine was well tolerated at most of the doses used in this study. Conclusions: In this pilot study, D-Cycloserine treatment resulted in significant improvement in social withdrawal. Further controlled studies Of D-cycloserine in autism appear warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available